Episode Details
Back to Episodes
Adagrasib: New Hope for KRAS G12C Lung Cancer
Published 5 days, 1 hour ago
Description
Adagrasib, a new drug targeting KRAS G12C mutation in lung cancer, shows promising results in clinical trials, shrinking tumors and delaying progression. This personalized treatment approach, part of a broader trend in medicine, could become a standard option if approved by the FDA, marking a significant step forward in lung cancer treatment.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/a33989eac7f2cc2e